Barclays began coverage on shares of ZimVie (NASDAQ:ZIMV – Get Rating) in a research report report published on Wednesday, The Fly reports. The brokerage issued an underweight rating and a $9.00 target price on the stock.
ZimVie Price Performance
NASDAQ:ZIMV opened at $8.52 on Wednesday. The business's 50-day moving average price is $8.68 and its 200 day moving average price is $13.30. ZimVie has a 52-week low of $6.67 and a 52-week high of $50.40. The company has a quick ratio of 1.48, a current ratio of 2.51 and a debt-to-equity ratio of 0.76.
Get
ZimVie alerts:
ZimVie (NASDAQ:ZIMV – Get Rating) last released its earnings results on Wednesday, November 9th. The company reported $0.49 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.27 by $0.22. The firm had revenue of $214.58 million for the quarter, compared to analyst estimates of $214.83 million. ZimVie had a negative return on equity of 2.75% and a negative net margin of 9.96%. As a group, sell-side analysts predict that ZimVie will post 1.95 EPS for the current fiscal year.
Hedge Funds Weigh In On ZimVie
A number of institutional investors have recently bought and sold shares of the stock. Point72 Hong Kong Ltd purchased a new position in ZimVie in the 3rd quarter worth about $27,000. US Bancorp DE acquired a new stake in ZimVie during the 3rd quarter worth about $36,000. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in ZimVie during the 3rd quarter worth about $46,000. Tower Research Capital LLC TRC acquired a new stake in ZimVie during the 3rd quarter worth about $47,000. Finally, Strs Ohio acquired a new stake in ZimVie during the 3rd quarter worth about $47,000. Hedge funds and other institutional investors own 74.29% of the company's stock.
ZimVie Company Profile
(Get Rating)
ZimVie Inc, a medical technology company, develops, manufactures, and delivers a portfolio of products and solutions designed to treat a range of spine pathologies, and support dental tooth replacement and restoration procedures worldwide. It offers dental implant systems, prosthetic and abutment products, surgical instrumentation, and kits; bone grafts, barrier membranes, allografts, and collagen wound care products; intraoral scanners; and virtual treatment planning services, guided surgery solutions, CAD/CAM workflow systems, and patient-specific restorative components and intra-oral scanners, as well as spinal fusion implants and instrumentation for various spinal procedures, biologics, and bone healing technologies.
Read More
- Get a free copy of the StockNews.com research report on ZimVie (ZIMV)
- MarketBeat: Week in Review 12/19 – 12/23
- These Steelmakers Deserve A Place On Your 2023 Watch List
- Inflation Cools, Where Does The S&P 500 Go Now
- Cintas Beats Inflation With Operating Leverage
- Your Decision to Buy Palantir May Simply Be a Matter of Time
Receive News & Ratings for ZimVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZimVie and related companies with MarketBeat.com's FREE daily email newsletter.
